Auranova Lifescience Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 20-06-2024
- Paid Up Capital ₹ 0.10 M
as on 20-06-2024
- Company Age 8 Year, 10 Months
- Last Filing with ROC 31 Mar 2022
- Revenue -81.20%
(FY 2020)
- Profit -16522.01%
(FY 2020)
- Ebitda 95.50%
(FY 2020)
- Net Worth -156.57%
(FY 2020)
- Total Assets -56.86%
(FY 2020)
About Auranova Lifescience
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Binay Kumar and Siddharth serve as directors at the Company.
- CIN/LLPIN
U33111DL2016PTC290066
- Company No.
290066
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Jan 2016
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
South West Delhi, Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Auranova Lifescience Private Limited offer?
Auranova Lifescience Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Fitness Supplements, Mineral Supplement, Anti Allergic Drug, Allergy Relief Tablets, Coenzyme Q10 Tablets and Capsules, Calcium Tablet, Calcium Citrate and Vitamin D3 Tablet, Dietary Supplements, Omega 3 Capsule.
Who are the key members and board of directors at Auranova Lifescience?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Binay Kumar  | Director | 19-Mar-2020 | Current |
| Siddharth | Additional Director | 19-Nov-2022 | Current |
Financial Performance of Auranova Lifescience.
Auranova Lifescience Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 81.2% decrease. The company also saw a substantial fall in profitability, with a 16522.01% decrease in profit. The company's net worth observed a substantial decline by a decrease of 156.57%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Auranova Lifescience?
In 2020, Auranova Lifescience had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Auranova Lifescience?
Unlock and access historical data on people associated with Auranova Lifescience, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Auranova Lifescience, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Auranova Lifescience's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
